Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CNTO edges out of 'hand-to-mouth' era

CNTO edges out of 'hand-to-mouth' era Centocor Inc. put in place another piece in its plan to find partners for its products, announcing on Friday that it signed a letter of intent with Wellcome plc to develop and market Panorex and six other monoclonal antibodies for cancer.

CNTO's strategy, since it suspended a second Phase III trial of its HA-1A sepsis antibody in

Read the full 702 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers